Monthly Prescribing Reference

Entyvio Injection Now Available

Takeda announced the availability of Entyvio (vedolizumab) injection for the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD). The FDA approved ...
Monthly Prescribing Reference

Entyvio Injection Approved for UC, Crohn’s Disease

ENTYVIO (vedolizumab) injection The FDA announced the approval of Entyvio (vedolizumab; Takeda) injection for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to ...
pharmaphorum

Takeda's Entyvio outperforms AbbVie's Humira in GI trial

Takeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – AbbVie’s Humira – in severely active ulcerative colitis. The results are ...
Nasdaq

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

− ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy “With the FDA approval of subcutaneous ENTYVIO, patients and ...
FierceBiotech

FDA approves Entyvio to treat ulcerative colitis and Crohn's disease

The U.S. Food and Drug Administration today approved Entyvio (vedolizumab) injection to treat adult patients with moderate to severe ulcerative colitis and adult patients with moderate to severe Crohn ...
PMLiVE

Takeda’s subcutaneous Entyvio approved by FDA as Crohn’s disease maintenance therapy

Takeda has announced that its subcutaneous (SC) Entyvio (vedolizumab) has been approved by the US Food and Drug Administration (FDA) as a maintenance therapy for adults with moderately to severely ...
Yahoo Finance

Takeda's Entyvio Tops AbbVie's Humira in Patients With Ulcerative Colitis

Shares of Takeda Pharmaceutical Co. Ltd. (TAK) jumped 1.93% to $20.63 on Monday after results from Phase 3B of the Varsity clinical trial showed the superiority of Takeda's Entyvio to AbbVie's (ABBV) ...
PMLiVE

Takeda’s subcutaneous Entyvio formulation faces FDA rejection

A subcutaneous formulation of Takeda’s key growth product Entyvio has been rejected by the FDA, as a maintenance treatment for adults with moderate-to-severe ulcerative colitis (UC). The anti-integrin ...
Healio

FDA approves subcutaneous Entyvio as maintenance therapy for ulcerative colitis

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...
PharmTech

Takeda Gets Approval in Japan for Entyvio Subcutaneous Injection

Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis. On March 27, 2023, Takeda Pharmaceutical announced that the ...
PharmiWeb

European Commission Approves Subcutaneous Formulation of Entyvio® (Vedolizumab) for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis ...

UC and CD are two of the most common forms of inflammatory bowel disease (IBD) and affect more than two million people in Europe. [1], [2] This decision by the European Commission means that Entyvio ...
AOL

Medicare coverage for Entyvio: What to know

Entyvio is a brand-name prescription biologic drug. It contains the active ingredient vedolizumab. Biosimilars are generic versions of biologic medications, but only the brand-name version of this ...